Hologic applies cutting-edge science to accelerate discovery, improve efficiency and continually sharpen precision. Breast Cancer Index is the first-and-only test recognized by national guidelines for prediction of extended endocrine therapy benefit in early-stage, HR+ breast cancer to know when extended endocrine therapy is beneficial and avoid it when it isn't.